Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on Duality Biologics — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Expansion of Collaboration between Duality Biologics and Adcendo ApS for ADC Pipeline Enhancement
Nov 26, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyTherapeuticsBiopharma
Description
Duality Biologics announced the expansion of its ongoing collaboration with Adcendo ApS, focusing on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. Adcendo exercised its option to utilize Duality’s technology platform to be used in additional assets, further strengthening its ADC pipeline.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months